1. The Cost-Effectiveness and Budget Impact of Introducing Indacaterol into the Colombian Health System 
Juan Guillermo Ariza, MD, MSc, Per-Olof Thuresson, MPharm, MSc, Gerardo Machnicki, MSc, PhD, Laura Mungapen, MSc, Matthias Kraemer, PhD, Yumi Asukai, MSc, Luis Fernando Giraldo, MD 
Value in Health Regional Issues 
Volume 1, Issue 2, Pages (December 2012)
DOI: /j.vhri
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

2. Fig. 1
Model structure. GOLD, Global Initiative for Chronic Obstructive Lung Disease.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

3. Fig. 2
Cost-effectiveness plane, indacaterol versus salmeterol/fluticasone (boxes) and indacaterol versus formoterol/budesonide (circles) based on the base-case analysis. For/Bud, formoterol/budesonide; NE, northeast; NW, northwest; QALY, quality-adjusted life-year; Sal/Flu, salmeterol/fluticasone; SE, southeast; SW, southwest.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions

4. Fig. 3
Cost-effectiveness acceptability curve for indacaterol versus tiotropium (dotted lines indicated 1×GDP and 3×GDP). GDP, gross domestic product; QALY, quality-adjusted life-year.
Value in Health Regional Issues 2012 1, DOI: ( /j.vhri )
Copyright © 2012 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Terms and Conditions